PDF herunterladen
Z Gastroenterol 2006; 44(2): 193-204
DOI: 10.1055/s-2005-858978
Übersicht

© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York

Die Antibiotika-assoziierte Diarrhö

Antibiotic-Associated DiarrheaO. Schröder1 , R. Gerhard2 , J. Stein1
  • 1Medizinische Klinik I - ZAFES, J.-W.-Goethe-Universität Frankfurt/Main
  • 2Institut für Toxikologie, Medizinische Hochschule Hannover
Weitere Informationen

Publikationsverlauf

Manuskript eingetroffen: 3.7.2005

Manuskript akzeptiert: 1.12.2005

Publikationsdatum:
03. Februar 2006 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Die Inzidenz der Antibiotika-assoziierten Diarrhö (AAD) schwankt in Abhängigkeit des verwendeten Antibiotikums zwischen 15 - 25 %. Die meisten Fälle einer AAD werden direkt oder indirekt durch Verschiebungen in der intestinalen Mikroflora verursacht, die über eine funktionelle Veränderung des intestinalen Kohlenhydrat- und Gallensäuremetabolismus in einer Diarrhö resultiert. Darüber hinaus begünstigt die Veränderung der mikrobiellen Flora die Proliferation pathogener Keime. Clostridium difficile zeichnet für 10 - 15 % aller Fälle einer AAD und der überwiegenden Anzahl der Antibiotika-assoziierten pseudomembranösen Kolitis verantwortlich. Neuere Daten belegen zudem die Bedeutung von Klebsiella oxytoca in der Entstehung einer Antibiotika-assoziierten hämorrhagischen Kolitis. Die Diagnose einer Clostridium-difficille-assoziierten Diarrhö stützt sich auf den Keim- und Toxinnachweis im Fäzes. Als Therapie der Wahl gilt die Behandlung mit Metronidazol, während die Gabe von Vancomycin oral Patienten vorbehalten sein sollte, die entweder auf Metronidazol nicht angesprochen haben oder bei denen eine Kontraindikation oder eine Intoleranz gegenüber diesem Antbiotikum vorliegt. Ein restriktiver Einsatz von Antibiotika (insbesondere Clindamycin und Cephalosporine), die Einhaltung einfacher Hygienemaßnahmen sowie die Gabe von Probiotika, wie Saccharomyces boulardii, haben sich in der Prophylaxe einer AAD als effektiv erwiesen.

Abstract

The incidence of antibiotic-associated diarrhea (AAD) differs with the antibiotic and varies from 15 - 25 %. Most cases of AAD are directly or indirectly caused by alterations of gut microflora by the antibiotics resulting in clinically mild AAD cases due to functional disturbances of intestinal carbohydrate or bile acid metabolism. Alternatively, changes in the gut flora allow pathogens to proliferate. Clostridium difficile is responsible for 10 - 15 % of all cases of AAD and almost of all cases of antibiotic-associated pseudomembraneous colitis. There is also a growing body of evidence which supports the responsibility of Klebsiella oxytoca for the development of antibiotic-associated hemorrhagic colitis. Diagnosing Clostridium difficile-associated diarrhea should be based both on fecal-cytotoxin detection and culture. With respect to specific therapy, metronidazol has become the first choice whereas treatment with oral vancomycin should be reserved for patients who have contraindications or intolerance to or who have failed to respond to metronidazole. Probiotics such as Sacharomyces boulardii can reduce the risk of development. Restrictive antibiotic policies (e. g. restricting clindamycin and cephalosporins) and the implementation of a comprehensive hospital infection control have also been shown to be effective in reducing the incidence of AAD.

Schlüsselwörter

Antibiotikum - Kolitis - Clostridium difficile

Key words

Antibiotic - Colitis - Clostridium difficile

Literatur

  • 1 Aboudola S, Kotloff K L, Kyne L. et al . Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A.  Infect Immun. 2003;  44 1608-1610
    PubMedGoogle Scholar
  • 2 Apisarnthanarak A, Razavi B, Mundy L M. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature.  Clin Infect Dis. 2002;  44 690-696
    PubMedGoogle Scholar
  • 3 Ariano R E, Zhanel G G, Harding G K. The role of anion-exchange resins in the treatment of antibiotic-associated pseudomembranous colitis.  CMAJ. 1990;  44 1049-1051
    PubMedGoogle Scholar
  • 4 Aslam S, Hamill R J, Musher D. Treatment of Clostridium difficile-associated disease: odd therapies and new strategies.  Lancet Infect Dis. 2005;  44 549-557
    PubMedGoogle Scholar
  • 5 Barbut F, Richard A, Hamadi K. et al . Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea.  J Clin Microbiol. 2000;  44 2386-2388
    PubMedGoogle Scholar
  • 6 Bartlett J G. Clinical practice. Antibiotic-associated diarrhea.  N Engl J Med. 2002;  44 334-339
    PubMedGoogle Scholar
  • 7 Beales I L. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea.  Gut. 2002;  44 456
    PubMedGoogle Scholar
  • 8 Bellaiche G, Le Pennec M P, Choudat L. Value of rectosigmoidoscopy with bacterial culture of colonic biopsies in the diagnosis of post-antibiotic hemorrhagic colitis related to Klebsiella oxycota.  Gastroenterol Clin Biol. 1997;  44 910-915
    PubMedGoogle Scholar
  • 9 Beloosesky Y, Grosman B, Marmelstein V. et al . Convulsions induced by metronidazole treatment for Clostridium difficile-associated disease in chronic renal failure.  Am J Med Sci. 2000;  44 338-339
    PubMedGoogle Scholar
  • 10 Bergogne-Bérézin E. Treatment and prevention of antibiotic-associated colitis. Guglietta A Pharmacotherapy of Gastrointestinal Inflammation Basel, Boston, Berlin; Birkhäuser Verlag 2004: 77-92
    Google Scholar
  • 11 Berrington A, Brriello P, Brazier J. et al . National Clostridium difficile Standards Group: report to the department of health.  J Hosp Infect. 2004;  44 1-38
    PubMedGoogle Scholar
  • 12 Beugerie L, Metz M, Barbut F. et al . Klebsiella oxytoca as an agent of antibiotic-associated hemorrhagic colitis.  Clin Gastroenterol Hepatol. 2003;  44 370-376
    PubMedGoogle Scholar
  • 13 Bleichner G, Blehaut H, Mentec H. et al . Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial.  Intensive Care Med. 1997;  44 517-523
    PubMedGoogle Scholar
  • 14 Bliss D Z, Johnson S, Savik K. et al . Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding.  Ann Intern Med. 1998;  44 1012-1019
    PubMedGoogle Scholar
  • 15 Bolton R P, Culshaw M A. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile.  Gut. 1986;  44 1169-1172
    PubMedGoogle Scholar
  • 16 Borriello S P, Hammes W P, Holzapfel W. et al . Safety of probiotics that contain lactobacilli or bifidobacteria.  Clin Infect Dis. 2003;  44 775-780
    PubMedGoogle Scholar
  • 17 Bricker E, Garg R, Nelson R. et al . Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.  Cochrane Database Syst Rev. 2005;  44 CD004610
    PubMedGoogle Scholar
  • 18 Brown E, Talbot G H, Axelrod P. et al . Risk factors for Clostridium difficile toxin-associated diarrhea.  Infect Control Hosp Epidemiol. 1990;  44 283-290
    PubMedGoogle Scholar
  • 19 Buggy B P, Fekety R, Silva J. et al . Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin.  J Clin Gastroenterol. 1987;  44 155-159
    PubMedGoogle Scholar
  • 20 Caron F, Ducrotte P, Lerebours E. et al . Effects of amoxicillin-clavulate combination on the motility of the small intestine in human beings.  Antimicrob Agents Chemother. 1991;  44 1085-1088
    PubMedGoogle Scholar
  • 21 Clausen M R, Bonnen H, Tvede M. et al . Colonic fermentation to short-chain fatty acids is decreased in antibiotic-associated diarrhea.  Gastroenterology. 1991;  44 411-417
    PubMedGoogle Scholar
  • 22 Climo M W, Israel D S, Wong E S. et al . Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost.  Ann Intern Med. 1998;  44 989-995
    PubMedGoogle Scholar
  • 23 Cremonini F, Di Caro S, Nista E C. et al . Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea.  Aliment Pharmacol Ther. 2002;  44 1461-1467
    PubMedGoogle Scholar
  • 24 Cunningham R, Dale B, Undy B. et al . Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea.  J Hosp Infect. 2003;  44 243-245
    PubMedGoogle Scholar
  • 25 D’Souza A L, Rajkumar C, Cooke J. et al . Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis.  BMJ. 2002;  44 1361
    PubMedGoogle Scholar
  • 26 de Lalla F, Nicolin R, Rinaldi E. et al . Prospective study of oral teicoplanin versus vancomycin for therapy of pseudomembraneous colitis and Clostridium difficile-associated diarrhea.  Antimicrob Agents Chemother. 1992;  44 2192-2196
    PubMedGoogle Scholar
  • 27 Delmée M, Van Broeck J, Simon A. et al . Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture.  J Med Microbiol. 2005;  44 187-191
    PubMedGoogle Scholar
  • 28 Delmée M, Vandercam B, Avesani V. et al . Epidemiology and prevention of Clostridium difficile infections in a leukemia unit.  Eur J Clin Microbiol. 1987;  44 623-627
    PubMedGoogle Scholar
  • 29 Dietrich C F, Lembcke B, Seifert H. et al . Sonographische Diagnostik der Penicillin-induzierten segmentär-hämorrhagischen Colitis.  Dtsch Med Wschr. 2000;  44 755-760
    PubMedGoogle Scholar
  • 30 Dobbins W O 3rd, Herrero B A, Mansbach C M. Morphologic alterations associated with neomycin induced malabsorption.  Am J Med Sci. 1968;  44 63-77
    PubMedGoogle Scholar
  • 31 Donskey C J. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens.  Clin Infect Dis. 2004;  44 219-226
    PubMedGoogle Scholar
  • 32 Dudley M N, McLaughlin J C, Carrington G. et al . Oral bacitracin vs vancomycin therapy for Clostridium difficile-associated diarrhea. A randomized double-blind rial.  Arch Intern Med. 1986;  44 1101-1104
    PubMedGoogle Scholar
  • 33 Fekety R, McFarland L V, Surawicz C M. et al . Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial.  Clin Infect Dis. 1997;  44 324-333
    PubMedGoogle Scholar
  • 34 Fekety R, Silva J, Kauffman C. et al . Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens.  Am J Med. 1989;  44 15-19
    PubMedGoogle Scholar
  • 35 Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee.  Am J Gastroenterol. 1997;  44 739-750
    PubMedGoogle Scholar
  • 36 Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease.  J Clin Gastroenterol. 2004;  44 414-418
    PubMedGoogle Scholar
  • 37 Friedenberg F, Fernandez A, Kaul V. et al . Intravenous metronidazole for the treatment of Clostridium difficile colitis.  Dis Colon Rectum. 2001;  44 1176-1180
    CrossrefPubMedGoogle Scholar
  • 38 Fuhrman M P. Diarrhea and tube feeding: The treatment of diarrhea in tube-fed patients.  Nutr Clin Pract. 1999;  44 84-87
    PubMedGoogle Scholar
  • 39 Garbutt J M, Littenberg B, Evanoff B A. et al . Enteric carriage of vancomycin-resistant Enterococcus faecium in patients tested for Clostridium difficile.  Infect Control Hosp Epidemiol. 1999;  44 664-670
    PubMedGoogle Scholar
  • 40 Gerding D N, Johnson S, Peterson L R. et al . Clostridium difficile-associated diarrhea and colitis.  Infect Control Hosp Epidemiol. 1995;  44 459-477
    PubMedGoogle Scholar
  • 41 Gerding D N. Treatment of Clostridium difficile-associated diarrhea and colitis.  Curr Top Microbiol Immunol. 2000;  44 127-139
    PubMedGoogle Scholar
  • 42 Goldhill J M, Rose K, Percy W H. Effects of antibiotics on epithelial ion transport in the rabbit distal colon in-vitro.  J Pharm Pharmacol. 1996;  44 555-558
    PubMedGoogle Scholar
  • 43 Gorbach S L, Chang T W, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG.  Lancet. 1987;  44 1519
    PubMedGoogle Scholar
  • 44 Guerrant R L, Van Gilder T, Steiner T S. et al . Practice guidelines for the management of infectious diarrhea.  Clin Infect Dis. 2001;  44 331-351
    PubMedGoogle Scholar
  • 45 Heer M, Sulser H, Hany A. Segmental hemorrhagic colitis following amoxicillin therapy.  Schweiz Med Wochenschr. 1989;  44 733-735
    PubMedGoogle Scholar
  • 46 Heerze L D, Kelm M A, Talbot J A. et al . Oligosaccharide sequences attached to an inert support (SYNSORB) as potential therapy for antibiotic-associated diarrhea and pseudomembranous colitis.  J Infect Dis. 1994;  44 1291-1296
    PubMedGoogle Scholar
  • 47 Higaki M, Chida T, Takano H. et al . Cytotoxic component(s) of Klebsilla oxytoca on HeEp-2 cells.  Microbiol Immunol. 1990;  44 764-767
    PubMedGoogle Scholar
  • 48 Hofmann A F. Bile acids, diarrhea, and antibiotics: data, speculation, and a unifying hypothesis.  J Infect Dis. 1977;  44 S126-S132
    PubMedGoogle Scholar
  • 49 Jarvis W R. Epidemiology, appropriateness, and cost of vancomycin use.  Clin Infect Dis. 1998;  44 1200-1203
    PubMedGoogle Scholar
  • 50 Johnson S, Homann S R, Bettin K M. et al . Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial.  Ann Intern Med. 1992;  44 297-302
    PubMedGoogle Scholar
  • 51 Johnson S, Samore M H, Farrow K A. et al . Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals.  N Engl J Med. 1999;  44 1645-1651
    PubMedGoogle Scholar
  • 52 Johnson S, Sanchez J L, Gerding D N. Metronidazole resistance in Clostridium difficile.  Clin Infect Dis. 2000;  44 625-626
    PubMedGoogle Scholar
  • 53 Johnson S, Gerding D N. Clostridium dificile-associated diarrhea.  Clin Infect Dis. 1998;  44 1027-1036
    PubMedGoogle Scholar
  • 54 Just I, Gerhard R. Large clostridial cytotoxins.  Rev Physiol Biochem Pharmacol. 2004;  44 23-47
    PubMedGoogle Scholar
  • 55 Karlstrom O, Fryklund B, Tullus K. et al . Swedish C. difficile study group: A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden.  Clin Infect Dis. 1998;  44 141-145
    PubMedGoogle Scholar
  • 56 Khan R, Cheesbrough J. Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital.  J Hosp Infect. 2003;  44 104-108
    PubMedGoogle Scholar
  • 57 Kerr R B, McLaughlin D I, Sonnenberg L W. Control of Clostridium difficile colitis outbreak by treating asymptomatic carriers with metronidazole.  Am J Infect Control. 1990;  44 332-335
    PubMedGoogle Scholar
  • 58 Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial.  Aliment Pharmacol Ther. 2005;  44 583-590
    PubMedGoogle Scholar
  • 59 Kyne L, Warny M, Qamar A. et al . Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.  Lancet. 2001;  44 189-193
    PubMedGoogle Scholar
  • 60 Leung D Y, Kelly C P, Boguniewicz M. et al . Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin.  J Pediatr. 1991;  44 633-637
    PubMedGoogle Scholar
  • 61 Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study.  Clin Gastroenterol Hepatol. 2005;  44 442-448
    PubMedGoogle Scholar
  • 62 Ludlam H, Brown N, Sule O. et al . An antibiotic policy associated with reduced risk of Clostridium difficile-associated diarrhea.  Age Aging. 1999;  44 578-580
    PubMedGoogle Scholar
  • 63 Massey V, Gregson D B, Chagla A H. et al . Clinical usefulness of components of the Triage immunoassay, enzyme immunoassay for toxins A and B, and cytotoxin B tissue culture assay for the diagnosis of Clostridium difficile diarrhea.  Am J Clin Pathol. 2003;  44 45-49
    PubMedGoogle Scholar
  • 64 Mayfield J L, Leet T, Miller J. et al . Environmental control to reduce transmission of Clostridium difficile.  Clin Infect Dis. 2000;  44 995-1000
    PubMedGoogle Scholar
  • 65 McFarland L V, Elmer G W, Surawicz C M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.  Am J Gastroenterol. 2002;  44 1769-1775
    PubMedGoogle Scholar
  • 66 McFarland L V, Mulligan M E, Kwok R Y. et al . Nosocomial acquisition of Clostridium difficile infection.  N Engl J Med. 1989;  44 204-210
    PubMedGoogle Scholar
  • 67 McFarland L V, Surawicz C M, Greenberg R N. et al . A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.  JAMA. 1994;  44 1913-1918
    PubMedGoogle Scholar
  • 68 McFarland L V. Alternative treatments for Clostridium difficile disease: what really works?.  J Med Microbiol. 2005;  44 101-111
    PubMedGoogle Scholar
  • 69 McNulty C, Logan M, Donald I P. et al . Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy.  J Antimicrob Chemother. 1997;  44 707-711
    PubMedGoogle Scholar
  • 70 Minami J, Saito S, Yoshida T. et al . Biological activities and chemical composition of a cytotoxin of Klebsiella oxytoca.  J Gen Microbiol. 1992;  44 1921-1927
    PubMedGoogle Scholar
  • 71 Moulis H, Vender R J. Antibiotic-associated hemorrhagic colitis.  J Clin Gastroenterol. 1994;  44 227-231
    PubMedGoogle Scholar
  • 72 Mrowka C, Munch R, Rezzonico M. et al . Acute segmental hemorrhagic penicillin-associated colitis.  Dtsch Med Wochenschr. 1990;  44 1750-1753
    PubMedGoogle Scholar
  • 73 Nomura K, Matsumoto Y, Yoshida N M. et al . Successful treatment with rifampin for fulminant antibiotics-associated colitis in a patient with non-Hodgkin’s lymphoma.  World J Gastroenterol. 2004;  44 765-766
    PubMedGoogle Scholar
  • 74 Pear S M, Williamson T H, Bettin K M. et al . Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use.  Ann Intern Med. 1994;  44 272-277
    PubMedGoogle Scholar
  • 75 Pelaez T, Alcacia L, Alonso R. et al . Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.  Antimicrob Agents Chemother. 2002;  44 1647-1650
    PubMedGoogle Scholar
  • 76 Pépin J, Valiquette L, Alary M E. et al . Clostridium difficile - associated diarrhea in a region of Quebec from 1991 to 2003.  A changing pattern of disease severity CMAJ. 2004;  44 466-472
    PubMedGoogle Scholar
  • 77 Pépin J, Alary M E, Valiquette L. et al . Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.  Clin Infect Dis. 2005a;  44 1591-1579
    PubMedGoogle Scholar
  • 78 Pépin, J, Saleh N, Coulombe M A. et al . Emergence of fluoroquinolones as the predominat risk factor for clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.  Clin Infect Dis. 2005b;  44 1254-1260
    PubMedGoogle Scholar
  • 79 Persky S E, Brandt L J. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope.  Am J Gastroenterol. 2000;  44 3283-3285
    PubMedGoogle Scholar
  • 80 Pochapin M. The effect of probiotics on Clostridium difficile diarrhea.  Am J Gastroenterol. 2000;  44 S11-S13
    PubMedGoogle Scholar
  • 81 Poutanen S M, Simor A E. Clostridium difficile-associated diarrhea in adults.  CMAJ. 2004;  44 51-58
    PubMedGoogle Scholar
  • 82 Rao S S, Edwards C A, Austen C J. et al . Impaired colonic fermentation of carbohydrate after ampicillin.  Gastroenterology. 1988;  44 928-932
    PubMedGoogle Scholar
  • 83 Riley T V. Nosocomial diarrhea due to Clostridium difficile.  Curr Opin Infect Dis. 2004;  44 323-327
    PubMedGoogle Scholar
  • 84 Rupnik M, Dupuy B, Fairweather N F. et al . Revised nomenclature of Clostridium difficile toxins and associated genes.  J Med Microbiol. 2005;  44 113-117
    PubMedGoogle Scholar
  • 85 Sakurai Y, Tsuchiya H, Ikegami F. et al . Acute right-sided hemorrhagic colitis associated with oral administration of ampicillin.  Dig Dis Sci. 1979;  44 910-915
    PubMedGoogle Scholar
  • 86 Salcedo J, Keates S, Pothoulakis C. et al . Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.  Gut. 1997;  44 366-370
    PubMedGoogle Scholar
  • 87 Shim J K, Johnson S, Samore M H. et al . Primary symptomless colonization by Clostridium difficile and decreased risk of subsequent diarrhea.  Lancet. 1998;  44 633-636
    PubMedGoogle Scholar
  • 88 Sougioultzis S, Kyne L, Drudy D. et al . Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea.  Gastroenterology. 2005;  44 764-770
    PubMedGoogle Scholar
  • 89 Surawicz C M, McFarland L V, Elmer G. et al . Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii.  Am J Gastroenterol. 1989;  44 1285-1287
    PubMedGoogle Scholar
  • 90 Surawicz C M, McFarland L V, Greenberg R N. et al . The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii.  Clin Infect Dis. 2000;  44 1012-1017
    PubMedGoogle Scholar
  • 91 Szajewska H, Mrukowicz J. Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea.  Aliment Pharmacol Ther. 2005;  44 365-372
    PubMedGoogle Scholar
  • 92 Takamine F, Imanura T. Isolation and characterization of bile acid 7-dehydroxylating bacteria from human feces.  Microbiol Immunol. 1995;  44 11-18
    PubMedGoogle Scholar
  • 93 Teasley D G, Gerding D N, Olson M M. et al . Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficille-associated diarrhea and colitis.  Lancet. 1983;  44 1043-1046
    PubMedGoogle Scholar
  • 94 Thomas C, Stevenson M, Williamson D J. et al . Clostridium difficile-associated diarrhea: epidemiological data from Western Australia associated with a modified antibiotic policy.  Clin Infect Dis. 2002;  44 1457-1462
    PubMedGoogle Scholar
  • 95 Thomas C, Stevenson M, Riley T V. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review.  J Antimicrob Chemother. 2003;  44 1339-1350
    PubMedGoogle Scholar
  • 96 Turgeon D K, Novicki T J, Quick J. et al . Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay.  J Clin Microbiol. 2003;  44 667-670
    PubMedGoogle Scholar
  • 97 van Dissel J T, de Groot N, Hensgens C M. et al . Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data.  J Med Microbiol. 2005;  44 197-205
    PubMedGoogle Scholar
  • 98 Voth D E, Ballard J D. Clostridium difficile Toxins: Mechanism of action and role in disease.  Clin Microbiol Rev. 2005;  44 247-263
    PubMedGoogle Scholar
  • 99 Wenisch C, Parschalk B, Hasenhundl M. et al . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea.  Clin Infect Dis. 1996;  44 813-818
    PubMedGoogle Scholar
  • 100 Wilcox M H, Fawley W N, Settle C D. et al . Recurrence of symptoms in Clostridium difficile infection-relapse or reinfection?.  J Hosp Infect. 1998;  44 93-100
    PubMedGoogle Scholar
  • 101 Wilcox M H. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea.  J Antimicrob Chemother. 2004;  44 882-884
    PubMedGoogle Scholar
  • 102 Wilcox M H. Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis.  Best Pract Res Clin Gastroenterol. 2003;  44 475-493
    PubMedGoogle Scholar
  • 103 Wilkins T D, Lyerly D M. Clostridium difficile testing: after 20 years, still challenging.  J Clin Microbiol. 2003;  44 531-534
    PubMedGoogle Scholar
  • 104 Wistrom J, Norrby S R, Myhre E B. et al . Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study.  J Antimicrob Chemother. 2001;  44 43-50
    PubMedGoogle Scholar
  • 105 Wullt M, Hagslatt M L, Odenholt I. Lactobacillus plantarum 299 v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial.  Scand J Infect Dis. 2003;  44 365-367
    PubMedGoogle Scholar
  • 106 Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea.  J Antimicrob Chemother. 2004;  44 211-216
    PubMedGoogle Scholar
  • 107 Young G P, Ward P B, Bayley N. et al . Antibiotic-associated colitis due to Clostridium difficile: Double-blind comparison of vancomycin with bacitracin.  Gastroenterology. 1985;  44 1038-1045
    PubMedGoogle Scholar
  • 108 Zafar A B, Gaydos L A, Furlong W B. et al . Effectiveness of infection control program in controlling nosocomial Clostridium difficile.  Am J Infect Control. 1998;  44 588-593
    PubMedGoogle Scholar

Jürgen Stein

Medizinische Klinik I - ZAFES, J. W. Goethe-Universität Frankfurt

Theodor-Stern-Kai 7

60590 Frankfurt/Main

Telefon: ++ 49/69/63 01 59 17

Fax: ++ 49/69/6 30 18 31 12

eMail: J.Stein@em.uni-frankfurt.de